MARKET

AXNX

AXNX

Axonics Modulation Technologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

49.93
-0.01
-0.02%
After Hours: 49.93 0 0.00% 16:13 10/26 EDT
OPEN
49.91
PREV CLOSE
49.94
HIGH
50.28
LOW
48.48
VOLUME
333.07K
TURNOVER
--
52 WEEK HIGH
52.10
52 WEEK LOW
15.25
MARKET CAP
1.97B
P/E (TTM)
-19.0871
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dow Jones Sheds Early Gains Into The Close But Remains Positive; Microsoft, Apple Form New Buy Points
Investor's Business Daily · 6d ago
Axonics® Launches ARTISTRY Study to Collect and Analyze Real-World Data of Patients Implanted with the Axonics r-SNM System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has launched a new post-market clinical registry study to collect and analyze real-world data of patients treated with the Axonics r-SNM® System.
Business Wire · 6d ago
Unusual Options Activity Insight: Axonics Modulation Tech
Axonics Modulation Tech (NASDAQ: AXNX) shares experienced unusual options activity on Wednesday. The stock price moved down to $47.4 following the option alert. * Sentiment: BULLISH * Option Type: TRADE * Trade Type: CALL * Expiration Date: 2020-11-20 * Strike Price: $50.00 * Volume: 766 * Open Interest: 3312Three Ways Options Activity Is 'Unusual'Exceptionally large volume (compared to historical averages) is one reason for which options market activity can be considered unusual. The volume of options activity refers to the number of contracts traded over a given time period. The number of unsettled contracts that have been traded, but not yet closed, is called open interest. These contracts are not yet closed because a buyer has not purchased the contract, or a seller has not sold it.Another indicator of unusual options activity is the trading of a contract with an expiration date in the distant future. Additional time until a contract expires generally increases the potential for it to grow its time value and reach its strike price. It is important to consider time value because it represents the difference between the strike price and the value of the underlying asset.Contracts that are "out of the money" are also indicative of unusual options activity. "Out of the money" contracts occur when the underlying price is under the strike price on a call option, or above the strike price on a put option. These trades are made with the expectation that the value of the underlying asset is going to change dramatically in the future, and buyers and sellers will benefit from a greater profit margin.Bullish And Bearish Sentiments Options are "bullish" when a call is purchased at/near ask price or a put is sold at/near bid price. Options are "bearish" when a call is sold at/near bid price or a put is bought at/near ask price.Although the activity is suggestive of these strategies, these observations are made without knowing the investor's true intentions when purchasing these options contracts. An observer cannot be sure if the bettor is playing the contract outright or if they're hedging a large underlying position in a common stock. For the latter case, the exposure a large investor has on their short position in common stock may be more meaningful than bullish options activity.Trading Options With These Strategies Unusual options activity is an advantageous strategy that may greatly reward an investor if they are highly skilled, but for the less experienced trader, it should remain as another tool to make an educated investment decision while taking other observations into account.For more information to understand options alerts, visit https://pro.benzinga.help/en/articles/1769505-how-do-i-understand-options-alertsSee more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Stocks That Hit 52-Week Highs On Thursday * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/14 14:26
Axonics® to Report Third Quarter 2020 Results on November 4
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report third quarter 2020 financial results and provide an operational update after the market closes on Wednesday, November 4, 2020.
Business Wire · 10/14 10:00
Beyond Meat, Nike Among 4 Leaderboard Breakout Stocks To Watch
Investor's Business Daily · 10/08 18:48
The 21-Day Exponential Moving Average: Why This Is Your New Edge
Investor's Business Daily · 10/06 00:45
Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previously implanted with
Business Wire · 10/05 13:00
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 1)
Benzinga · 10/02 11:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXNX. Analyze the recent business situations of Axonics Modulation Technologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXNX stock price target is 55.56 with a high estimate of 77.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 168
Institutional Holdings: 30.76M
% Owned: 77.82%
Shares Outstanding: 39.52M
TypeInstitutionsShares
Increased
60
8.72M
New
45
1.25M
Decreased
28
2.72M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.17%
Healthcare Equipment & Supplies
-0.88%
Key Executives
Chairman/Independent Director
Michael Carrel
President/Chief Financial Officer
Dan Dearen
Chief Executive Officer/Director
Raymond Cohen
Chief Financial Officer/Chief Operating Officer/Primary Contact
Danny Dearen
Chief Operating Officer
Rinda Sama
Chief Marketing Officer
John Woock
Other
Alfred Ford
Other
Prabodh Mathur
Other
Karen Noblett
Independent Director
Erik Amble
Independent Director
Jane Kiernan
Independent Director
Robert McNamara
Independent Director
Nancy Snyderman
Independent Director
Juliet Tammenoms Bakker
Director
Juliet Bakker
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AXNX
Axonics Modulation Technologies, Inc. is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, which typically lasts a few days to a few weeks, and a permanent implant for those patients who experience a successful external trial period.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Axonics Modulation Technologies Inc stock information, including NASDAQ:AXNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXNX stock methods without spending real money on the virtual paper trading platform.